(257 days)
Not Found
No
The device description and performance studies focus on standard ion-specific electrode technology and traditional analytical methods, with no mention of AI or ML.
No
The device is described as an electrolyte buffer and reagents used for the quantitative determination of certain electrolytes in bodily fluids, which is for diagnostic purposes, not therapeutic treatment or prevention.
Yes
The device is intended for the "quantitative determination of sodium, potassium, chloride, and total CO2 in serum and plasma, and sodium, potassium and chloride in urine, and Reference will also determine calcium in serum, plasma and urine," and the results are explicitly stated to be used for "diagnosis and treatment of" various medical conditions, clearly indicating a diagnostic purpose.
No
The device description explicitly states the use of "Ion Specific Electrodes" and "ISE Solution," which are hardware components. The performance studies are also conducted on a "Beckman CX3® Synchron Analyzer," a piece of hardware.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the device is for the "quantitative determination of sodium, potassium, chloride, and total CO2 in serum and plasma, and sodium, potassium and chloride in urine, and Reference will also determine calcium in serum, plasma and urine." These are measurements performed on biological samples in vitro (outside the body).
- Diagnostic Purpose: The intended use also clearly links the results of these measurements to the "diagnosis and treatment" of various diseases and conditions involving electrolyte imbalance, acid-base balance, parathyroid diseases, chronic renal disease, and tetany. This indicates a diagnostic purpose.
- Device Description: The description mentions the use of "Ion Specific Electrodes" to determine the concentration of electrolytes in the sample, which is a common method used in in vitro diagnostic testing.
- Performance Studies: The document details performance studies like precision, linearity, sensitivity, analytical specificity, and patient comparison, which are standard evaluations for IVD devices to demonstrate their analytical performance.
- Predicate Device: The mention of a predicate device with the name "Electrode, Ion Specific, Sodium, Potassium, Chloride, CO2, Calcium" further confirms that this device falls within the category of IVD products used for electrolyte analysis.
All these factors align with the definition of an In Vitro Diagnostic device, which is a medical device intended for use in vitro for the examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological or pathological state, or a congenital abnormality, or to monitor therapeutic measures.
N/A
Intended Use / Indications for Use
GenChem ISE Electrolyte Buffer, when used in conjunction with the GenChem ISE Electrolyte Reference, GenChem CO2 Acid Reagent, GenChem CO2 Alkaline Buffer, GenChem Wash Concentrate, and appropriate Calibrators or Calibration Standards, is intended for the quantitative determination of sodium, potassium, chloride, and total CO2 in serum and plasma, and sodium, potassium and chloride in urine, and Reference will also determine calcium in serum, plasma and urine.
Sodium results are for the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by the destruction of the adrenal glands), dehvdration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. Potassium results are used to monitor electrolyte imbalance in the diagnosis and treatment of diseases and conditions characterized by low or high blood potassium levels. Chloride results are used in the treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis. Carbon dioxide results are used in the diagnosis and treatment of numerous and potentially serious disorders associated with changes in the body's acid-base balance. Calcium results are used in the diagnosis and treatment of parathyroid diseases, chronic renal disease and tetany (intermittent muscular contractions or spasm).
Product codes (comma separated list FDA assigned to the subject device)
JGS, CEM, CGZ, JFL, JFP
Device Description
Sodium, Potassium, Chloride, CO2 and Calcium are determined by the use of Ion Specific Electrodes, the conductivity of which is proportional to the concentration of electrolyte in the sample which is mixed with high ionic strength buffer using the ISE Solution as the reference.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Prescription Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
- Precision/Reproducibility: Within-Day and Day-to-Day precision was determined according to NCCLS EP5-A.
- Linearity/assay reportable range: Linearity was performed according to NCCLS Guideline EP6-A. Commercially available linearity standards were analyzed in triplicate on the Beckman CX3® and the results analyzed by the Least Squares method.
- Sensitivity: The sensitivity of this methodology was documented through the repetitive assay of a serum control first with a known concentration and then diluting the sample until the minimum result was obtained and then run in replicates of 10 on the Beckman Synchron® System.
- Analytical Specificity: Determined according to NCCLS EP7-A. Hemoglobin levels up to 500 mg/dL, Bilirubin levels up to 20 mg/dL, and Lipemia levels up to 1800 mg/dL were tested and did not show any adverse effect on a stock sample with levels of sodium at 148 mmol/L, potassium at 5.2 mmol/L, chloride at 119 mmol/L, CO2 at 19 mmol/L, and calcium at 9.4 mg/dL.
- Patient Comparison: Serum, plasma, cerebrospinal fluid and urine specimens, collected from adult patients, were assayed for calcium, chloride, potassium, sodium, and total CO2 on a SYNCHRON CX3® System using GenChem and Beckman flow cell reagents, wash solutions and calibrators. Results were compared by least squares linear regression where X = Beckman Results and Y = GenChem Results. Sample sizes included 80 for serum/plasma (calcium, chloride, potassium, sodium, total CO2), 74 for urine (calcium), 78 for urine (chloride, sodium), 44 for CSF (chloride), and 80 for urine (potassium).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity/Limit of Detection:
Calcium: 1.5 mg/dL
Sodium: 10 mmol/L
Potassium: 1.0 mmol/L
Chloride: 15 mmol/L
Total CO2: 5.0 mmol/L
Linearity:
Calcium: 0.8 to 14.3 mg/dL
Chloride: 0 to 150 mmol/L
Potassium: 0.9 to 15.2 mmol/L
Sodium: 0 to 200 mmol/L
Total CO2: 0 to 40 mmol/L
Patient Comparison (r values):
Calcium: Serum 0.985, Plasma 0.995, Urine 0.998
Chloride: Serum 0.935, Plasma 0.985, Urine 0.999, CSF 0.985
Potassium: Serum 1.000, Plasma 1.000, Urine 1.000
Sodium: Serum 0.938, Urine 1.000
Total CO2: Serum 0.953, Plasma 0.960
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1665 Sodium test system.
(a)
Identification. A sodium test system is a device intended to measure sodium in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.(b)
Classification. Class II.
0
DEC 27 2004
510(k) SUMMARY K040977
1.0 Submitted By:
C.C. Allain, Ph.D. Chief Scientific Officer GenChem, Inc. 471 W. Lambert Road, Ste 107 Brea, CA 92821 Telephone: (714) 529-7125 FAX: (714) 529-3339
2.0 Date of Preparation: June 1, 2004
3.0 Regulatory Information:
- 3.1 Regulation section: GenChem Electrolyte Buffer 21 CFR § 862.1665 Electrode, Ion Specific, Sodium, Potassium, Chloride, CO2, Calcium
- 3.2 Clasification : Class II
- 3.3 Product Code: JGS
- 3.4 Panel: Clinical Chemistry (75)
4.0 Device Description:
Sodium, Potassium, Chloride, CO2 and Calcium are determined by the use of Ion Specific Electrodes, the conductivity of which is proportional to the concentration of electrolyte in the sample which is mixed with high ionic strength buffer using the ISE Solution as the reference.
- 5.0 a. Predicate Device Name: Electrode, Ion Specific, Sodium, Potassium, Chloride, CO2, Calcium
- b. Predicate K Number: K801896
- c. Comparison with Predicate: Both Reagents are similar in design, function and chemical principle as well as ingredient composition and concentration.
- 6.0 Performance Characteristics: All studies were performed on the Beckman CX3® Synchron Analyzer
- 6.1 Precision/Reproducibility: Within-Day and Day-to-Day precision was determined according to NCCLS EP5-A. Results are summarized below:
1
Within-Day; N=60
S-1 S-2 S-3 U-1 U-2
|
00m |
1
ALL AL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL ALL | 1 | - |
-
| (
1 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I matting a man a later i more in the let the letter lines
AT
and and the collection of the control of the comments of the closes | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 10-40-4-4-4-4-4000
of and I for there a
0
A ANNAL AND ALL A CALL A |
1 | ANNA A AL-AL-
1
00 | 1
on an exper sense in a come
1
œ | |
| (
on an experience of the comments of the contract and consisted and consisted and consisted to the
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 1
wound of a can all the consider the consideration of the consideration | 1 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
100 100
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------
-------------------------------------- | A LAND LA A LA
1 80 10 100
A 10 year
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | |
Day-To-Day (30 Days); N=60
S-1 S-2 U-1 U-2 S-3
| AN MARKER BLA CORRES OF A
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 4164
vear
mmo |
1 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
And State | ANNUAL A COLLECTION OF
1
ﺮﻳﺔ ﻓﻲ ﺍﻟﻤﻬﺎﺟﺮ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪ | 1
J | (
1
A famil a family |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I | S S S S S F L C L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L . L
15 The
And Separat
44-4-4-4-4-4-4-4- | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 1
Call Property and Children College of | 1 Class | i
A = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = |
| A AND AND A LAND - L A - A -- A | N. None on Local Come I di
0/01/
ت ت
----------- | 14.44
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | | I
1 4 m | ) | |
6.2 Linearity/assay reportable range:
Linearity was performed according to NCCLS Guideline EP6-A. Commercially available linearity standards were analyzed in triplicate on the Beckman CX3® and the results analyzed by the Least Squares method. The results are shown below. Specimens exceeding these limits should be diluted with normal saline and reanalyzed. Multiply the result by the appropriate dilution factor.
| Intercept | Slope | R2 | Sey | Range | |
|---|---|---|---|---|---|
| Calcium | 0.34 | 0.911 | 1.000 | 0.35 | 0.8 – 14.3 mg/dL |
| Na | 2.37 | 0.968 | 1.000 | 2.61 | 0 – 200 mmol/L |
| K | -0.09 | 1.017 | 1.000 | 0.03 | 0.9 – 15.2 mmol/L |
| CL | -0.71 | 0.999 | 1.000 | 0.99 | 0 – 197 mmol/L |
| CO2 | 0.15 | 1.000 | 1.000 | 0.41 | 0 – 40 mmol/L |
2
The results show this method is linear as shown below:
| Calcium | 0.8 to 14.3 mg/dl |
|---|---|
| Chloride | 0 to 150 mmol/L |
| Potassium | 0.9 to 15.2 mmol/L |
| Sodium | 0 to 200 mmol/L |
| Total CO2 | 0 to 40 mmol/L |
6.3 SENSITIVITY:
The sensitivity of this methodology was documented through the repetitive assay of a serum control first with a known concentration and then diluting the sample until the minimum result was obtained and then run in replicates of 10 on the Beckman Synchron® System. Under the conditions described, the following limits of detection were established:
| Analyte | Limit of Detection |
|---|---|
| Calcium | 1.5 mg/dL |
| Sodium | 10 mmol/L |
| Potassium | 1.0 mmol/L |
| Chloride | 15 mmol/L |
| Total CO2 | 5.0 mmol/L |
- 6.4 Analytical Specificity:
Determined according to NCCLS EP7-A. Hemoglobin levels up to 500 mg/dL, Bilirubin levels up to 20 mg/dL, and Lipemia levels up to 1800 mg/dL were tested and did not show any adverse effect on a stock sample with levels of sodium at 148 mmol/L, potassium at 5.2 mmol/L, chloride at 119 mmol/L, CO2 at 19 mmol/L, and calcium at 9.4 mg/dL. Stock solutions of the substance to be tested were prepared at 20x concentrations and 0.5 ml of this stock was placed in a 10 ml volumetric flask and made up to volume with the base pool. The control stock was prepared similarly but with water as the diluent. Only Sodium Heparin, Lithium Heparin and Ammonium Heparin up to 45 Units/mL are acceptable anticoagulants.
3
7.0 PATIENT COMPARISON :
Serum, plasma, cerebrospinal fluid and urine specimens, collected from adult patients, were assayed for calcium, chloride, potassium, sodium, and total CO2 on a SYNCHRON CX3® System using GenChem and Beckman flow cell reagents, wash solutions and calibrators. Results were compared by least squares linear regression where X = Beckman Results and Y = GenChem Results.
| Analyte Specimen | Unit | n | m | b | r | range |
|---|---|---|---|---|---|---|
| Calcium | ||||||
| Serum | mg/dL | 80 | 0.989 | 0.0 | 0.985 | 7.1-10.6 |
| Plasma | mg/dL | 80 | 0.990 | 0.0 | 0.995 | 7.1-10.7 |
| Urine | mg/dL | 74 | 1.007 | -0.2 | 0.998 | 2.4-15.2 |
| Chloride | ||||||
| Serum | mmol/L | 80 | 0.988 | 1.0 | 0.935 | 98 - 127 |
| Plasma | mmol/L | 80 | 0.998 | 0.8 | 0.985 | 98 - 127 |
| Urine | mmol/L | 78 | 1.049 | -5.1 | 0.999 | 22-289 |
| CSF | mmol/L | 44 | 1.024 | -3.4 | 0.985 | 113-152 |
| Potassium | ||||||
| Serum | mmol/L | 80 | 0.969 | 0.13 | 1.000 | 3.2-10.8 |
| Plasma | mmol/L | 80 | 0.987 | 0.15 | 1.000 | 3.2-10.8 |
| Urine | mmol/L | 80 | 0.993 | 0.01 | 1.000 | 3.5-136 |
| Sodium | ||||||
| Serum | mmol/L | 80 | 0.930 | 9.1 | 0.938 | 132-159 |
| Urine | mmol/L | 78 | 1.000 | -0.3 | 1.000 | 17-288 |
| Total CO2 | ||||||
| Serum | mmol/L | 80 | 0.949 | 1.2 | 0.953 | 9.5-29 |
| Plasma | mmol/L | 80 | 0.965 | 0.9 | 0.960 | 9.5-29 |
8.0 Expected Values/ Reference Range:
The expected values for calcium, chloride, potassium, sodium, and total CO2 are listed below. Use these ranges only as guides. Each laboratory should establish its own reference ranges.
Reference Ranges1
| Analyte | Specimen | Conventional Units | SI Units |
|---|---|---|---|
| Calcium | Serum/Plasma | 8.4 - 10.2 mg/dL | 2.10 - 2.55 mmol/L |
| Urine | 100 - 300 mg/day | 2.5 - 7.5 mmol/day | |
| Chloride | Serum/Plasma | 101 - 111 mmol/L | same |
| Urine | 110 - 250 mmol/day | same | |
| CSF | 118 - 132 mmol/L | same | |
| Potassium | Serum/Plasma | 3.5 - 5.1 mmol/L | same |
| Urine | 25 - 125 mmol/day | same | |
| Sodium | Serum/Plasma | 136 - 145 mmol/L | same |
| Urine | 40 - 220 mmol/day | same | |
| Total CO2 | Serum/Plasma | 22 - 28 mmol/L | same |
4
Image /page/4/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features an abstract eagle design with three stylized wing segments. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle. The seal is black and white.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 27 2004
C.C. Allain. Ph.D. Chief Scientific Officer GenChem, Inc. 471 W. Lambert Road, Suite 107 Brea, CA 92821
K040977 Re:
Trade/Device Name: GenChem ISE Electrolyte Buffer Regulation Number: 21 CFR 862.1665 Regulation Name: Sodium test system Regulatory Class: Class II Product Code: JGS, CEM, CGZ, JFL, JFP Dated: October 15, 2004 Received: October 15, 2004
Dear Dr. Allain:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sincerely yours,
Cornelia B. Parks
Cornelia B. Rooks, MA Acting Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
INDICATIONS FOR USE
510(k) Number: K040977
Device Name: GenChem ISE Electrolyte Buffer
Indications For Use:
GenChem ISE Electrolyte Buffer, when used in conjunction with the GenChem ISE Electrolyte Reference, GenChem CO2 Acid Reagent, GenChem CO2 Alkaline Buffer, GenChem Wash Concentrate, and appropriate Calibrators or Calibration Standards, is intended for the quantitative determination of sodium, potassium, chloride, and total CO2 in serum and plasma, and sodium, potassium and chloride in urine, and Reference will also determine calcium in serum, plasma and urine.
Sodium results are for the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by the destruction of the adrenal glands), dehvdration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. Potassium results are used to monitor electrolyte imbalance in the diagnosis and treatment of diseases and conditions characterized by low or high blood potassium levels. Chloride results are used in the treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis. Carbon dioxide results are used in the diagnosis and treatment of numerous and potentially serious disorders associated with changes in the body's acid-base balance. Calcium results are used in the diagnosis and treatment of parathyroid diseases, chronic renal disease and tetany (intermittent muscular contractions or spasm).
A.berto C
Division Sign-Off
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
5100k K040977
Prescription Use X
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)